Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Greer Receives FDA Approval To Begin Sublingual-Oral Immunotherapy Trial

By Pharmaceutical Processing | January 11, 2005

LENOIR, NC (January 10, 2005) — Greer Laboratories, Inc., a provider of allergy immunotherapy products and services, has received Food & Drug Administration (FDA) approval to begin Phase I safety and dosing studies focused on sublingual-oral administration of dust mite allergenic extracts.

Dust mite is one of the most prevalent allergens. Of the roughly 50 million people who suffer from allergies in the United States, approximately 15 percent are sensitive to the dust mite allergens. It is estimated that an additional 10 to 15 million people remain undiagnosed.

“The approval to move forward with our safety and dosing trials marks a major milestone for Greer’s R&D sublingual clinical program,” states Bob Esch, Ph.D, Greer chief scientist.

The World Health Organization now classifies allergy as the fourth most important disease in the world and estimates that by 2010, approximately 40 percent to 50 percent of the world’s population could be affected.

In the United States, approximately 3 million of the 50 million allergy sufferers are treated with predominantly subcutaneous immunotherapy. Sublingual immunotherapy is delivered via the patient’s oral mucosa.

“Sublingual immunotherapy is of interest to some allergists because it offers a potential alternative for patients who may not be treated with injection immunotherapy,” stated Dr. Spencer Atwater, former president of the Joint Council of Allergy, Asthma & Immunology

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards